- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.01. | After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones | 468 | AFX News | BEIJING (dpa-AFX) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical... ► Artikel lesen | |
| 13.01. | Rapid Micro Biosystems reports Q4 results | 1 | Seeking Alpha | ||
| 13.01. | Rapid Micro Biosystems reports 37% revenue growth in Q4 2025 | 4 | Investing.com | ||
| 13.01. | Rapid Micro Biosystems reports preliminary fourth quarter revenue | 2 | Seeking Alpha | ||
| 13.01. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue | 1.026 | GlobeNewswire (Europe) | Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period.Received record multi-system order in the fourth... ► Artikel lesen | |
| 13.01. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | - | SEC Filings | ||
| RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
| 11.11.25 | Rapid Micro Biosystems: GrowthDirect-Plattform im Fokus der Wachstumsstrategie | 2 | Investing.com Deutsch | ||
| 07.11.25 | Rapid Micro Biosystems raises 2025 revenue guidance to at least $33M amid record multi-system order and accelerating margin improvement | 2 | Seeking Alpha | ||
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. Q3 Loss Misses Estimates | 1 | RTTNews | ||
| 07.11.25 | Rapid Micro Biosystems: EPS verfehlt Schätzungen um 0,01 $ - Umsatz besser als erwartet | 3 | Investing.com Deutsch | ||
| 07.11.25 | Rapid Micro Biosystems GAAP EPS of -$0.26 misses by $0.02, revenue of $7.84M beats by $0.24M | 1 | Seeking Alpha | ||
| 07.11.25 | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance | 152 | GlobeNewswire (Europe) | Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual... ► Artikel lesen | |
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.25 | Earnings Outlook For Rapid Micro Biosystems | 4 | Benzinga.com | ||
| 28.10.25 | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Third Quarter 2025 Financial Results on November 7, 2025 | 2 | GlobeNewswire (USA) | ||
| 22.09.25 | Trinity Capital provides $45M in growth capital to Rapid Micro Biosystems | 21 | Seeking Alpha | ||
| 13.08.25 | Stifel bestätigt Kaufempfehlung für Rapid Micro Biosystems und hält an Kursziel von 8 US-Dollar fest | 18 | Investing.com Deutsch | ||
| 13.08.25 | Stifel reiterates Buy rating on Rapid Micro Biosystems stock, maintains $8 target | 2 | Investing.com | ||
| 12.08.25 | Rapid Micro Biosystems reaffirms $32M revenue guidance for 2025 as recurring revenue climbs 15% | 2 | Seeking Alpha |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,360 | +1,40 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
RAPID MICRO BIOSYSTEMS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,870 Euro und damit +4,88 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPID MICRO BIOSYSTEMS INC finden Sie auf Wallstreet Online.